Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Amazon

A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks.

2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands

Deere & Company

DoubleVerify Holdings

Lamb Weston Hlds

Vertiv Holdings Co

Deere, fresh off Friday's strong earnings move, leads this weekend's watch list of 5 stocks near buy points. The post Deere Leads 5 Stocks With Hot Products Near Buy Points appeared first on Investor's Business Daily.

Deere Leads 5 Stocks With Hot Products Near Buy Points

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom G7 Continuous Glucose Monitoring System Will be Available to Medicare Beneficiaries at Launch

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch

DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong

DexCom, Inc. (NASDAQ:DXCM ) Q4 2022 Earnings Conference Call February 9, 2023 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance & Investor Relations Jereme Sylvain - Executive Vice President & Chief Financial Officer Kevin Sayer - Executive Chairman, Chief Executive Officer & President Conference Call Participants Jeff Johnson - Baird Larry Beigelsen - Wells Fargo Robbie Marcus - JPMorgan Joanne Wuensch - Citibank Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Travis Steed - Bank of America Jayson Bedford - Raymond James Matt Taylor - Jefferies Mathew Blackman - Stifel Chris Pasquale - Nephron Kyle Rose - Canaccord Steve Lichtman - Oppenheimer Josh Jennings - Cowen Cecilia Furlong - Morgan Stanley Matt Miksic - Barclays Michael Polark - Wolfe Research Operator Ladies and gentlemen, welcome to the DexCom Fourth Quarter 2022 Earnings Release Conference Call. My name is Abby and I will be your operator for today's call.

DexCom, Inc. (DXCM) Q4 2022 Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates

Dexcom stock rose late Thursday after beating fourth-quarter expectations and reiterating its 2023 sales outlook. The post Dexcom Advances On Fourth-Quarter Beat, Reiterates Its 2023 Sales Expectations appeared first on Investor's Business Daily.

Dexcom Advances On Fourth-Quarter Beat, Reiterates Its 2023 Sales Expectations

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #cgm--Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

DarioHealth

New integration will improve access to Dario's multi-chronic platform for more people living with diabetes NEW YORK , Feb. 8, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today an agreement with Dexcom (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring (CGM) technology, to integrate its market-leading CGMs, into Dario's multi-chronic condition platform.     Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health.

Dario Partners to Integrate Dexcom CGM Data

Shopify

These companies have rock-solid businesses that can enrich investors over the long term.

2 Stock-Split Stocks to Buy Without Hesitation in 2023

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

Embecta Corp

DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued.

Diabetes Deep-Dive With DexCom And Embecta: Polar Opposite Diabetes Plays

TORONTO--( BUSINESS WIRE )--Mednow Inc. (“Mednow” or the “Company”) (TSXV: MNOW) (OTCQX: MDNWF) announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital diabetes management solution, to enable convenient on-demand access to Dexcom G6 (NASDAQ: DXCM) real-time continuous glucose monitoring (rtCGM) supplies and personalized diabetes care services.

Mednow Launches New Virtual Diabetes Management Program in Partnership With Dexcom

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time

AbbVie

Abbott Labs

Becton, Dickinson and Co.

Bruker

Danaher

Edwards Lifesciences

Medtronic

Merck KGaA

Thermo Fisher Scientific

The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.

Ranking The Diversified Healthcare Giants

Apple

Costco

Alphabet

NVIDIA

Study after study shows that a long-term buy-and-hold investing strategy works best. A long-term investment is generally defined as any position in a stock that is held for a year or longer.

The Top 7 “Millionaire-Maker” Long-Term Stocks for 2023

BURNABY, British Columbia--( BUSINESS WIRE )--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Starbucks

The new year is here, and with it, more opportunities to invest in wonderful companies.

2 Best Stocks to Buy in January and Hold Forever

Let's consider a combination of two strategies involving options with the goal being to collect as much premium upfront and minimizing our risk. The post As Dexcom Settles, 2 Option Strategies Collect Premium, Minimize Risk appeared first on Investor's Business Daily.

As Dexcom Settles, 2 Option Strategies Collect Premium, Minimize Risk

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.

DexCom (DXCM) Announces Solid Preliminary Q4 Revenues

This company offers products that are essential to the well-being of its customers.

1 Top Growth Stock That Could Beat the Market In 2023 and Beyond

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic1 basis. U.S. revenue is expected to be approximately $606 million, representing growth of 17% over the fourth quarter of 2021. International revenue is expected to be approximately $209 million, an increase of 15% over the fourth quarter of 2021 on a reported basis and 26% on an organic1 basis.

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer experience.

Dexcom Appoints Teri Lawver as Chief Commercial Officer

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023.

News for DexCom Stock (DXCM)